Fleury SA operates within the Medical laboratories sector. In addition to historical fundamental analyses, the complete report available to purchase compares Fleury SA with three other pharmaceutical manufacturers in Latin America: Instituto Hermes Pardini SA (2020 sales of 1.49 billion Brazilian Reals [US$301.27 million] of which 100% was auxiliary diagnostic support services), Genomma Lab Internacional Sab De Cv of MEXICO (13.87 billion Mexican Pesos [US$681.58 million] of which 100% was PC), and Hypera SA (4.09 billion Brazilian Reals [US$824.52 million] ).

Sales Analysis. During the first quarter of 2021, sales at Fleury SA totalled 893.81 million Brazilian Reals. This is an increase of 25.2% from the 713.93 million Brazilian Reals in sales at the company during the first quarter of 2020. There appears to be at least some degree of seasonality in the sales at Fleury SA: during 8 of the previous 9 years, sales were highest during the third quarter. The exception to this was during 2020, when the fourth quarter was the best quarter, accounting for 31% of sales (during that same year, the third quarter accounted for 29% of sales). During the year ended December of 2020, sales at Fleury SA were 2.97 billion Brazilian Reals (US$599.23 million). This is an increase of 2.3% versus 2019, when the company's sales were 2.91 billion Brazilian Reals. This was the fifth consecutive year of sales increases at Fleury SA (and since 2015, sales have increased a total of 57%). Sales of Integrated Medicine saw an increase that was more than double the company's growth rate: sales were up 15.3% in 2020, from 467.62 million Brazilian Reals to 538.93 million Brazilian Reals. Not all segments of Fleury SA experienced an increase in sales in 2020: sales of Diagnostic Medicine fell 0.2% to 2.43 billion Brazilian Reals.